Thought Leadership

Latest Report

Obesity matters for drug developers

Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting sales by indication of $50bn in 2028 and CAGR between 2021 and 2028 at around 36%.  The R&D pipeline is filling up as more and more companies try to grab a slice of this…

Report library

Thumbnail

The Impact of Data Science

Digital technologies have plenty to offer a pharma industry seeking to up its productivity game. Attention often focuses artificial intelligence powered drug discovery or…

Thumbnail

ESMO 2022 eBook

The European Society of Medical Oncology Conference (ESMO) in Paris has wrapped up and there was much to talk about as Europe’s top oncologists came together to announce…

Thumbnail

PD(L)anner – September 2022

Once again, Evaluate Vantage provides the latest insights and expert perspectives on new developments in the PD-(L)1 inhibitor landscape. The last few months have been…